Related Experiment Video

Updated: May 13, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Simultaneous in vivo phenotyping of CYP enzymes

Sussan Ghassabian1, Michael Murray

  • 1Faculty of Pharmacy, University of Sydney, Sydney, NSW, Australia.

Methods in Molecular Biology (Clifton, N.J.)
|March 12, 2013
PubMed

Insights

Rapidly measuring drug-metabolizing enzyme (CYP) activity in patients using liquid chromatography-tandem mass spectrometry (LC-MS-MS) can personalize medicine. This 5-minute assay enables faster clinical decisions for drug efficacy and toxicity.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Clinical Chemistry

Background:

  • Cytochrome P450 (CYP) enzymes are critical determinants of drug efficacy and toxicity by influencing drug metabolism duration.
  • Personalized medicine requires rapid patient-specific data for optimizing drug therapy, especially for medications with narrow therapeutic indices or significant toxicity.
  • Current in vivo phenotyping methods for CYP activities can be time-consuming, limiting their immediate clinical utility.

Purpose of the Study:

  • To develop and validate a rapid, simultaneous assay for phenotyping multiple major drug-metabolizing CYP enzymes in patients.
  • To assess the feasibility of applying liquid chromatography-tandem mass spectrometry (LC-MS-MS) for near real-time CYP phenotyping in a clinical setting.

Main Methods:

  • Application of liquid chromatography-tandem mass spectrometry (LC-MS-MS) for simultaneous analysis.
  • Utilized a cocktail of well-tolerated, CYP-specific substrates for in vivo phenotyping.
  • Developed a 5-minute assay protocol for rapid sample processing and analysis.

Main Results:

  • Successfully demonstrated the simultaneous phenotyping of five major drug-metabolizing CYPs.
  • Achieved rapid assay turnaround time of 5 minutes, suitable for clinical decision-making.
  • Validated the LC-MS-MS method for accurate and precise quantification of CYP activities.

Conclusions:

  • The developed LC-MS-MS assay provides a rapid and efficient method for simultaneous in vivo phenotyping of major drug-metabolizing CYPs.
  • This approach has the potential to significantly advance personalized medicine by enabling timely, patient-specific therapeutic guidance.
  • Facilitates faster clinical decisions regarding drug efficacy and toxicity management.

More Related Videos

Multi-enzyme Screening Using a High-throughput Genetic Enzyme Screening System08:10

Multi-enzyme Screening Using a High-throughput Genetic Enzyme Screening System

Published on: August 8, 2016

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...